Semaglutide Weight Loss in Maine and New Hampshire

Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin signaling. Originally developed for type 2 diabetes, it has become one of the most clinically studied tools for sustained weight loss. At Med Matrix, semaglutide is prescribed as part of a broader protocol that includes lab work and lifestyle support, not as a standalone medication.

Before prescribing semaglutide, we run an 80-biomarker blood panel to identify what is driving your weight gain. Thyroid dysfunction, insulin resistance, hormonal imbalances, and chronic inflammation all contribute to stubborn weight. We address those root causes alongside the GLP-1 therapy so that results hold long term, not just while you are on the medication.

Full onboarding runs approximately $1,200 to $1,500 all-in, covering your 80-biomarker lab panel, InBody 770 body composition scan, provider prep time, and a full one-hour provider consultation. Semaglutide medication costs vary depending on your protocol. New patients receive a $100 voucher toward their first visit. We accept HSA and FSA accounts.

The most common side effects are nausea, mild digestive discomfort, and reduced appetite, especially in the first few weeks as your dose increases. Most patients tolerate the medication well when titrated gradually. Your provider monitors your labs and adjusts your protocol as needed throughout your program.

Semaglutide is appropriate for adults who have struggled to lose weight through diet and exercise alone, particularly those with insulin resistance, metabolic syndrome, or a BMI over 27 with a related health condition. During your first visit, your provider reviews your full lab panel and health history to determine whether semaglutide fits your goals and your biology.

Both are GLP-1 receptor agonists that reduce appetite and support weight loss. Tirzepatide also targets a second receptor (GIP), which may produce slightly greater weight loss in some patients. At Med Matrix, your provider reviews your full lab panel, metabolic markers, and health history to determine which medication fits your biology. The right choice depends on your individual results, not a generic recommendation.

Most patients notice reduced appetite and less food noise within the first two to four weeks. Measurable weight loss typically begins within the first month, with steady progress over three to six months as your dose is gradually increased. Your provider tracks your body composition with InBody scans at each visit, so you can see changes in fat mass and muscle mass separately, not just the number on the scale.

Yes. Semaglutide is FDA-approved for weight management in adults without diabetes. At Med Matrix, we prescribe it for patients with a BMI over 27 who have a weight-related health condition, or a BMI over 30. Your provider confirms eligibility based on your lab results and health history during your first visit.

The FDA is moving to permanently exclude semaglutide, tirzepatide, and liraglutide from large-scale (503B) compounding. The public comment period on that proposal was extended to July 30, 2026, but the agency's direction has not changed. Once the rule is finalized, the bulk supply behind most compounded GLP-1 programs will wind down. Med Matrix prescribes only FDA-approved semaglutide and tirzepatide, so the change does not affect our patients' supply.

Yes. Switching from a compounded vial to an FDA-approved medication is a clinical decision rather than a straight swap, since doses do not always map one-to-one. We start with an 80+ biomarker panel and an InBody 770 body composition scan to see where your health actually stands, then your provider builds the transition into a monitored protocol with gradual dose titration. A free discovery call is the first step.

Possibly, yes. Research presented at Heart Rhythm 2026 followed more than 13,000 patients and found GLP-1 medication use tied to a lower risk of atrial fibrillation, regardless of how much weight patients lost, including patients who gained weight. This is early cohort data, not a randomized trial, so it is not proof that semaglutide prevents heart rhythm problems. It does suggest the medication may support your cardiovascular system in ways the scale cannot show. Your provider tracks your labs and body composition throughout your program, so progress is measured by more than weight alone.

The FDA has sent three waves of warning letters to telehealth companies marketing compounded GLP-1s since September 2025, most recently 25 letters in June 2026, citing misleading claims that the product is the same as the FDA-approved drug and sellers that never disclose which pharmacy made the medication. The agency has also received hundreds of adverse event reports tied to compounded semaglutide, many from at-home dosing errors. Med Matrix prescribes FDA-approved GLP-1 medication after an 80+ biomarker panel, with InBody scans and provider follow-up throughout your program.

Yes, through the Medicare GLP-1 Bridge Program that launched July 1, 2026. Eligible Medicare Part D beneficiaries with a BMI of 27 or higher and a qualifying condition such as heart disease or prediabetes can get certain GLP-1 medications for a flat $50 monthly copay, with prior authorization required. Covered medications include all formulations of Wegovy and Foundayo and the KwikPen formulation of Zepbound. Compounded semaglutide is not included, the program runs through December 31, 2027, and the $50 copay does not count toward your Part D deductible or annual out-of-pocket cap. Med Matrix is a cash-pay clinic and does not bill Medicare. Our program covers the clinical side a pharmacy copay never includes: the 80+ biomarker panel, body composition tracking, and ongoing provider monitoring.

The $50 copay applies only inside the Bridge Program, which covers specific formulations and requires prior authorization through a central CMS system rather than your plan's usual process. Reporting from STAT News also found the 2025 federal pricing deal carried an unpublicized condition: private Medicare insurers had to agree to cover GLP-1s broadly at the $50 copay in exchange for the discounted price, so plans implement the coverage differently and the broad retail price cuts many patients expected never arrived. Ask your Part D plan about the Medicare GLP-1 Bridge Program by name, confirm your exact medication and formulation are covered, and get the copay in writing before your first fill.

A plateau is normal and expected. As you lose fat, your body burns fewer calories at rest and your appetite hormones adapt, so the same dose that worked at first produces a smaller deficit over time. In many cases the stall also points to something the medication was never going to fix on its own, like a sluggish thyroid, high fasting insulin, elevated cortisol, or muscle loss that has quietly slowed your metabolism. Early research even suggests the plateau is partly wired into how specific brain cells respond to the medication, though that work is still in animal models. Before we adjust your dose or switch medications, we recheck your labs and body composition to find the actual driver. Sometimes the answer is a higher dose, sometimes it's more protein and resistance training, and sometimes it's treating a hormone or thyroid issue that was stalling you all along.

No. Wegovy and Ozempic are both semaglutide, and Zepbound and Mounjaro are both tirzepatide. Within each pair the medication is identical, and the difference is the FDA label: Ozempic and Mounjaro carry type 2 diabetes approvals, while Wegovy and Zepbound are approved for chronic weight management. In the SURMOUNT-5 head-to-head trial, tirzepatide averaged 20.2 percent body weight loss over 72 weeks versus 13.7 percent for semaglutide, but the right fit depends on your labs, health history, and goals, which is exactly what the 80+ biomarker panel and your provider consultation are for. Our brand-name GLP-1 comparison on the blog covers the full picture.